Cosmos Health (NASDAQ:COSM) Releases Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Cosmos Health (NASDAQ:COSM) posted its quarterly earnings results on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.11), FiscalAI reports. The business had revenue of $18.99 million during the quarter, compared to the consensus estimate of $19.42 million. Cosmos Health had a negative net margin of 30.41% and a negative return on equity of 52.85%.

Cosmos Health Price Performance

COSM stock traded up $0.00 during mid-day trading on Tuesday, reaching $0.21. 2,325,400 shares of the company traded hands, compared to its average volume of 4,473,561. The company has a fifty day moving average price of $0.23 and a 200-day moving average price of $0.30. Cosmos Health has a 52-week low of $0.16 and a 52-week high of $1.32. The company has a market capitalization of $12.52 million, a P/E ratio of -0.33 and a beta of 4.80. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.08 and a quick ratio of 0.92.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Cosmos Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 30th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Insider Transactions at Cosmos Health

In other news, CEO Grigorios Siokas acquired 349,825 shares of the business’s stock in a transaction dated Thursday, July 30th. The stock was bought at an average cost of $0.20 per share, for a total transaction of $69,965.00. Following the completion of the transaction, the chief executive officer owned 14,597,917 shares of the company’s stock, valued at $2,919,583.40. The trade was a 2.46% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Georgios Terzis acquired 168,135 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was purchased at an average price of $0.25 per share, with a total value of $42,033.75. Following the completion of the transaction, the chief financial officer directly owned 2,235,398 shares of the company’s stock, valued at $558,849.50. This trade represents a 8.13% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders bought 2,204,138 shares of company stock worth $457,137. Insiders own 26.15% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of COSM. XTX Topco Ltd grew its position in shares of Cosmos Health by 52.1% during the 4th quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after purchasing an additional 34,117 shares in the last quarter. Citadel Advisors LLC raised its position in shares of Cosmos Health by 133.1% in the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after buying an additional 128,776 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Cosmos Health by 260.5% in the fourth quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock worth $167,000 after buying an additional 241,775 shares in the last quarter. 12.61% of the stock is owned by institutional investors.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.